BR112014026706A2 - método de tratamento para dermatoses responsivas a esteroides - Google Patents

método de tratamento para dermatoses responsivas a esteroides

Info

Publication number
BR112014026706A2
BR112014026706A2 BR112014026706A BR112014026706A BR112014026706A2 BR 112014026706 A2 BR112014026706 A2 BR 112014026706A2 BR 112014026706 A BR112014026706 A BR 112014026706A BR 112014026706 A BR112014026706 A BR 112014026706A BR 112014026706 A2 BR112014026706 A2 BR 112014026706A2
Authority
BR
Brazil
Prior art keywords
chloro
methyl
responsive dermatoses
treatment method
steroid
Prior art date
Application number
BR112014026706A
Other languages
English (en)
Inventor
Agarwal Pankaj
Xie Qing
Kumar Vinod
Original Assignee
Glaxosmithkline Ip No 2 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48143295&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112014026706(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Ip No 2 Ltd filed Critical Glaxosmithkline Ip No 2 Ltd
Publication of BR112014026706A2 publication Critical patent/BR112014026706A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

resumo “método de tratamento para dermatoses responsivas a esteroides” é inventado um método para tratar dermatoses responsivas a esteroides em um mamífero, incluindo um humano, em necessidade do mesmo que compreende administrar uma quantidade terapeuticamente eficaz de um composto selecionado do grupo que consiste em: n-{(1s)-2-amino-1-[(3-fluorofenil)metil]etil}-5-cloro-4-(4-cloro-1-metil-1h-pirazol-5-il)-2-tiofenocarboxamida ou um sal farmaceuticamente aceitável do mesmo, e o composto n-{(1s)-2-amino-1-[(3,4-difluorofenil)metil]etil}-5-cloro-4-(4-cloro-1-metil-1h-pirazol-5-il)-2-furancarboxamida ou um sal farmaceuticamente aceitável do mesmo, a esse mamífero.
BR112014026706A 2012-04-24 2013-04-22 método de tratamento para dermatoses responsivas a esteroides BR112014026706A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261637390P 2012-04-24 2012-04-24
US201361782565P 2013-03-14 2013-03-14
PCT/EP2013/058249 WO2013160222A1 (en) 2012-04-24 2013-04-22 Treatment method for steroid responsive dermatoses

Publications (1)

Publication Number Publication Date
BR112014026706A2 true BR112014026706A2 (pt) 2017-06-27

Family

ID=48143295

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014026706A BR112014026706A2 (pt) 2012-04-24 2013-04-22 método de tratamento para dermatoses responsivas a esteroides

Country Status (26)

Country Link
US (2) US20150087683A1 (pt)
EP (1) EP2841053A1 (pt)
JP (1) JP2015514792A (pt)
KR (1) KR20150010943A (pt)
CN (1) CN104302275A (pt)
AR (1) AR090795A1 (pt)
AU (1) AU2013254849B2 (pt)
BR (1) BR112014026706A2 (pt)
CA (1) CA2873751A1 (pt)
CL (1) CL2014002861A1 (pt)
CO (1) CO7111283A2 (pt)
CR (1) CR20140491A (pt)
DO (1) DOP2014000238A (pt)
EA (1) EA201491914A1 (pt)
HK (1) HK1201726A1 (pt)
IL (1) IL235159A0 (pt)
MX (1) MX2014012904A (pt)
NZ (1) NZ628394A (pt)
PE (1) PE20142356A1 (pt)
PH (1) PH12014502400A1 (pt)
SG (1) SG11201406409VA (pt)
TW (1) TW201347758A (pt)
UA (1) UA113875C2 (pt)
UY (1) UY34762A (pt)
WO (1) WO2013160222A1 (pt)
ZA (1) ZA201407345B (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111821299A (zh) * 2019-04-16 2020-10-27 天津合美医药科技有限公司 噻吩衍生物用于治疗免疫球蛋白E（IgE）介导的疾病的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006002734A1 (en) * 2004-07-01 2006-01-12 Unilever N.V. Moisture barrier
CA2578384A1 (en) * 2004-09-06 2006-03-16 Altana Pharma Ag Novel pyrazolopyrimidines
US7705014B2 (en) * 2005-04-12 2010-04-27 Merck Sharp & Dohme Corp. Inhibitors of AKT activity
UY30892A1 (es) * 2007-02-07 2008-09-02 Smithkline Beckman Corp Inhibidores de la actividad akt
SG172926A1 (en) * 2009-01-30 2011-08-29 Glaxosmithkline Llc Crystalline n-{(1-s)-2-amino-1-[(3-fluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1h-pyrazol-5-yl)-2-thiophenecarboxamide hydrochloride
CA2777085A1 (en) * 2009-10-08 2011-04-14 Glaxosmithkline Llc Combination
WO2011146710A1 (en) * 2010-05-21 2011-11-24 Glaxosmithkline Llc Combination

Also Published As

Publication number Publication date
US20150087683A1 (en) 2015-03-26
HK1201726A1 (en) 2015-09-11
IL235159A0 (en) 2014-12-31
CA2873751A1 (en) 2013-10-31
KR20150010943A (ko) 2015-01-29
AR090795A1 (es) 2014-12-10
WO2013160222A1 (en) 2013-10-31
AU2013254849A1 (en) 2014-11-06
EA201491914A1 (ru) 2015-01-30
PE20142356A1 (es) 2015-01-30
EP2841053A1 (en) 2015-03-04
JP2015514792A (ja) 2015-05-21
MX2014012904A (es) 2014-11-21
NZ628394A (en) 2016-02-26
UA113875C2 (uk) 2017-03-27
CO7111283A2 (es) 2014-11-10
PH12014502400A1 (en) 2015-01-12
CN104302275A (zh) 2015-01-21
UY34762A (es) 2013-11-29
TW201347758A (zh) 2013-12-01
ZA201407345B (en) 2015-11-25
CR20140491A (es) 2014-12-22
AU2013254849B2 (en) 2016-05-26
CL2014002861A1 (es) 2015-01-16
DOP2014000238A (es) 2014-12-15
SG11201406409VA (en) 2014-11-27
US20160143885A1 (en) 2016-05-26

Similar Documents

Publication Publication Date Title
MX2019004616A (es) Métodos de uso de indazol-3-carboxamidas y su uso como inhibidores de la ruta de señalización de wnt/b-catenina.
BR112017023233A2 (pt) métodos para tratamento de câncer
BR112017003546A2 (pt) amidas heterocíclicas como inibidores de rip1 quinase como medicamentos
WO2015054619A8 (en) Use of a pcsk9 inhibitor to treat hyperlipidemia
WO2015106128A3 (en) Rnai agents modified at the 4'-c-position
BR112015022197A2 (pt) tratamento de cataplexia
EA201500365A1 (ru) Комбинация регорафениба и ацетилсалициловой кислоты для лечения рака
BR112015021371A2 (pt) uso de agonistas de receptor de formil peptídeo 2 para tratar doenças inflamatórias oculares
BR112013030894A2 (pt) moduladores do sistema imune
AR097178A1 (es) Diagnóstico y terapias anticáncer que comprenden células madre cancerosas
IN2015DN00376A (pt)
EA201592254A1 (ru) Производные пиразолопирролидин-4-она и их применение при лечении заболевания
IN2015DN00450A (pt)
WO2015085143A3 (en) Therapeutic agents for skin diseases and conditions
BR112018003232A2 (pt) terapias de combinação para tratamento de câncer
BR112016027043A8 (pt) combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer
MX2017005861A (es) Metodos para el control transcripcional objetivo en regiones del super mejorador.
EA201890859A1 (ru) Предотвращение, лечение и обращение развития заболевания с применением терапевтически эффективных количеств активированных жирных кислот
EA201400002A1 (ru) Способы лечения заболеваний сетчатки
BR112013021566A2 (pt) composto de fórmula, ou um aduto ou sal farmaceuticamente aceitável do mesmo e método de prevenção e/ou tratamento de um indivíduo que compreende a administração ao dito indivíduo uma quantidade terapeuticamente eficaz de um composto de fórmula
BR112014010376A2 (pt) medicamento para o tratamento de doença do olho anterior que compreende rebamipida e um agente de retenção de lágrima
WO2014107730A3 (en) Use of fatty acid niacin conjugates for treating diseases
BR112015022846A2 (pt) uso de um composto para tratar ou prevenir um angioedema mediado pelo receptor b2 da bradicinina e formulação compreendendo o mesmo
BR112017007138A2 (pt) composto, medicamento, métodos para reduzir proteína 4 de ligação ao retinol e para a profilaxia ou o tratamento de degeneração macular e/ou uma doença, e, uso de um composto.
BR112014010729A2 (pt) métodos para tratamento de ataques de gota

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25A Requested transfer of rights approved

Owner name: NOVARTIS PHARMA AG (CH)

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25A Requested transfer of rights approved

Owner name: NOVARTIS AG (CH)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2515 DE 19-03-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.